HomeCompareSLLN vs JNJ

SLLN vs JNJ: Dividend Comparison 2026

SLLN yields 4000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLLN wins by $4.994481689239762e+42M in total portfolio value
10 years
SLLN
SLLN
● Live price
4000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.994481689239762e+42M
Annual income
$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00
Full SLLN calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SLLN vs JNJ

📍 SLLN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLLNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLLN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLLN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLLN
Annual income on $10K today (after 15% tax)
$340,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SLLN beats the other by $4,245,100,666,965,326,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLLN + JNJ for your $10,000?

SLLN: 50%JNJ: 50%
100% JNJ50/50100% SLLN
Portfolio after 10yr
$2.497240844619881e+42M
Annual income
$2,497,118,039,391,368,600,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SLLN
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLLN buys
0
JNJ buys
0
No recent congressional trades found for SLLN or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLLNJNJ
Forward yield4000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.994481689239762e+42M$30.3K
Annual income after 10y$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.994465620575748e+42M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLLN vs JNJ ($10,000, DRIP)

YearSLLN PortfolioSLLN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$400,010,700$400,000,000.00$10,592$272.30+$400.00MSLLN
2$14,954,099,039,486$14,953,671,028,037.38$11,289$357.73+$14954099.03MSLLN
3$522,475,570,786,797,700$522,459,569,900,825,500.00$12,123$472.89+$522475570786.79MSLLN
4$17,060,387,015,284,700,000,000$17,059,827,966,423,956,000,000.00$13,141$629.86+$17060387015284700.00MSLLN
5$520,629,757,399,644,800,000,000,000$520,611,502,785,538,400,000,000,000.00$14,408$846.81+$520629757399644831744.00MSLLN
6$14,848,629,939,995,690,000,000,000,000,000$14,848,072,866,155,271,000,000,000,000,000.00$16,021$1,151.60+$1.4848629939995692e+25MSLLN
7$395,786,651,827,842,740,000,000,000,000,000,000$395,770,763,793,806,900,000,000,000,000,000,000.00$18,122$1,588.22+$3.9578665182784276e+29MSLLN
8$9,859,464,902,403,675,000,000,000,000,000,000,000,000$9,859,041,410,686,219,000,000,000,000,000,000,000,000.00$20,930$2,228.20+$9.859464902403675e+33MSLLN
9$229,542,483,200,980,940,000,000,000,000,000,000,000,000,000$229,531,933,573,535,350,000,000,000,000,000,000,000,000,000.00$24,792$3,191.91+$2.2954248320098093e+38MSLLN
10$4,994,481,689,239,762,000,000,000,000,000,000,000,000,000,000,000$4,994,236,078,782,737,000,000,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.994481689239762e+42MSLLN

SLLN vs JNJ: Complete Analysis 2026

SLLNStock

Searchlight Solutions Ltd. provides training services to the insurance and financial service industries in the United Kingdom. The company offers technical skills, FCA regulatory, business skills, and financial services business consultancy and training services, as well as short intensive training courses and open workshops. It also provides training and competency support, financial services, and regulatory/compliance consultancy services, as well as in-house solutions by supplying trainers and training resources. The company offers its services through face-to-face training and e-learning solutions. It serves insurers, intermediaries, loss adjusters, and other insurance service providers. The company was founded in 1999 and is based in Leatherhead, the United Kingdom. As of July 5, 2018, Searchlight Solutions Ltd. operates as a subsidiary of Thistle Initiatives Limited.

Full SLLN Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SLLN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLLN vs SCHDSLLN vs JEPISLLN vs OSLLN vs KOSLLN vs MAINSLLN vs ABBVSLLN vs MRKSLLN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.